0.78Open0.78Pre Close0 Volume211 Open Interest7.00Strike Price0.00Turnover140.88%IV-0.51%PremiumJan 17, 2025Expiry Date0.82Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.6901Delta0.1258Gamma5.13Leverage Ratio-0.0216Theta0.0025Rho3.54Eff Leverage0.0070Vega
Grifols Stock Discussion
Benzinga· 3 mins ago
FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients
Welcome to the end of the dog days of summer for a while; my name is Kevin Travers, and here are stories from the moomoo herd on Wall Street today.
$Intel (INTC.US)$ traded higher after the firm said it had bypassed Vietnam for a $3.3B project and in...
2. $Inspire Veterinary Partners (IVP.US)$
3. $Dynatronics (DYNT.US)$
4. $Zapp Electric Vehicles (ZAPP.US)$
5. $Maxeon Solar Technologies (MAXN.US)$
6. $Grifols (GRFS.US)$
7. $SinglePoint (SING.US)$
8. $Venus Concept (VERO.US)$
9. $IDEAYA Biosciences (IDYA.US)$
10. $Kuke Music (KUKE.US)$
- Reuters
Benzinga· 1 min ago
No comment yet